Aim PET imaging with [18F]PM-PBB3 (a.k.a.[18F]APN-1607*) has demonstrated the capability of this radioligand for high-contrast visualization of tau deposits in the brains of Alzheimer’s disease (AD) and diverse other neurodegenerative disorders. Though it is desirable to perform sufficient duration of a dynamic PET scan to estimate accurate non-displaceable binding potential (BPND), imaging over 1 hour is impractical for a clinical setting. This study was aimed at optimizing a protocol for a 20-min static emission scan to obtain a reliable target-to-reference ratio of radioligand concentrations in comparison with analytical models with dynamic scan data and an arterial input function.Methods Ten subjects consisting of 5 healthy controls (HC...
Fluorine-18 labelled N,N-diethyl-2-(2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-α]pyrimidi...
Abstract Background Imaging agents capable of quantifying the brain’s tau aggregates will allow a mo...
Objective: To investigate characteristics of [11C]PBB3 binding andits relation with clinical aspects...
Aim PET imaging with [18F]PM-PBB3 ([18F]APN-1607) has demonstrated the capability of this radioligan...
Objectives A novel tau PET ligand, 18F-AM-PBB3, has been developed by structural modifications of ...
Background:We recently developed a novel fluorinated tau PET ligand, [18F]PM-PBB3, to improve charac...
Tau accumulation in the brain is a pathological hallmark of Alzheimer’s disease (AD) and other tauop...
A good understanding of the in vivo pharmacokinetics of radioligands is important for accurate PET q...
Molecular imaging of tauopathies is complicated by the differing specificities and off-target bindin...
[18F]THK5317 is a PET tracer for in-vivo imaging of tau associated with Alzheimer's disease (AD). Th...
Background and aims:[11C]PBB3 has been recently developed as a tau imaging PET ligand that has high ...
Alzheimer disease (AD) is associated with an increase in the brain of the 18-kDa translocator protei...
[11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main ob...
Background and Aims: 11C-PBB3 is a tau PET ligand that can visualize diverse tau pathologies includi...
The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET radioligan...
Fluorine-18 labelled N,N-diethyl-2-(2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-α]pyrimidi...
Abstract Background Imaging agents capable of quantifying the brain’s tau aggregates will allow a mo...
Objective: To investigate characteristics of [11C]PBB3 binding andits relation with clinical aspects...
Aim PET imaging with [18F]PM-PBB3 ([18F]APN-1607) has demonstrated the capability of this radioligan...
Objectives A novel tau PET ligand, 18F-AM-PBB3, has been developed by structural modifications of ...
Background:We recently developed a novel fluorinated tau PET ligand, [18F]PM-PBB3, to improve charac...
Tau accumulation in the brain is a pathological hallmark of Alzheimer’s disease (AD) and other tauop...
A good understanding of the in vivo pharmacokinetics of radioligands is important for accurate PET q...
Molecular imaging of tauopathies is complicated by the differing specificities and off-target bindin...
[18F]THK5317 is a PET tracer for in-vivo imaging of tau associated with Alzheimer's disease (AD). Th...
Background and aims:[11C]PBB3 has been recently developed as a tau imaging PET ligand that has high ...
Alzheimer disease (AD) is associated with an increase in the brain of the 18-kDa translocator protei...
[11C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main ob...
Background and Aims: 11C-PBB3 is a tau PET ligand that can visualize diverse tau pathologies includi...
The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET radioligan...
Fluorine-18 labelled N,N-diethyl-2-(2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-α]pyrimidi...
Abstract Background Imaging agents capable of quantifying the brain’s tau aggregates will allow a mo...
Objective: To investigate characteristics of [11C]PBB3 binding andits relation with clinical aspects...